Evaluating the efficacy and safety of antidepressants in patients with bipolar disorder

References

• Grande I, Berk M, Birmaher B, et al. Bipolar disorder. Lancet. 2016;387:1561–1572.
   PubMed Web of Science ®Google Scholar
• Goodwin FK, Jamison KR. Manic-depressive illness: bipolar disorders and recurrent depression. 2nd ed. Oxford: Oxford University Press; 2007.
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. ( DSM-5). Washington: American Psychiatric Publishing; 2013.
   Google Scholar
• Perlis RH, Smoller JW, Fava M, et al. The prevalence and clinical correlates of anger attacks during depressive episodes in bipolar disorder. J Affect Disord. 2004;79:291–295.
   PubMed Web of Science ®Google Scholar
• Goodwin GM. Bipolar depression and treatment with antidepressants. Br J Psychiatry. 2012;200:5–6.
   PubMed Web of Science ®Google Scholar
• Perlis RH, Miyahara S, Marangell LB, et al. Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry. 2004;55:875–881.
   PubMed Web of Science ®Google Scholar
• Han K-M, De Berardis D, Fornaro M, et al. Differentiating between bipolar and unipolar depression in functional and structural MRI studies. Prog Neuro-Psychopharmacology Biol Psychiatry. 2019;91:20–27.
   PubMed Web of Science ®Google Scholar
• Novis F, Cirillo P, Da Silva RA, et al. The progression of 102 Brazilian patients with bipolar disorder: outcome of first 12 months of prospective follow-up. Trends Psychiatry Psychother. 2014;36:16–22.
   PubMedGoogle Scholar
• Baldessarini RJ, Salvatore P, Khalsa H-MK, et al. Morbidity in 303 first-episode bipolar I disorder patients. Bipolar Disord. 2010;12:264–270.
   PubMed Web of Science ®Google Scholar
• Kupka RW, Altshuler LL, Nolen WA, et al. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord. 2007;9:531–535.
   PubMed Web of Science ®Google Scholar
• Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003;60:261–269.
   PubMed Web of Science ®Google Scholar
• Post RM. Treatment of bipolar depression. Psychiatr Clin North Am. 2016;39:11–33.
   PubMed Web of Science ®Google Scholar
• Hawton K, Sutton L, Haw C, et al. Suicide and attempted suicide in bipolar disorder: a systematic review of risk factors. J Clin Psychiatry. 2005;66:693–704.
   PubMed Web of Science ®Google Scholar
• Latalova K, Kamaradova D, Prasko J. Suicide in bipolar disorder: a review. Psychiatry Danub. 2014;26:108–114.
   PubMed Web of Science ®Google Scholar
• Leverich GS, Altshuler LL, Frye MA, et al. Factors associated with suicide attempts in 648 patients with bipolar disorder in the Stanley Foundation Bipolar Network. J Clin Psychiatry. 2003;64:506–515.
   PubMed Web of Science ®Google Scholar
• Valtonen HM, Suominen K, Mantere O, et al. Prospective study of risk factors for attempted suicide among patients with bipolar disorder. Bipolar Disord. 2006;8:576–585.
   PubMed Web of Science ®Google Scholar
• Isometsä ET, Henriksson MM, Aro HM, et al. Suicide in bipolar disorder in Finland. Am J Psychiatry. 1994;151:1020–1024.
   PubMed Web of Science ®Google Scholar
• Beyer JL. The use of antidepressants in bipolar depression. Handb Exp Pharmacol. 2019;250:415–442.
   PubMedGoogle Scholar
• H-J M, Grunze H, Broich K. Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? Eur Arch Psychiatry Clin Neurosci. 2006;256:1–16.
   PubMed Web of Science ®Google Scholar
• Fountoulakis KN. An update of evidence-based treatment of bipolar depression: where do we stand? Curr Opin Psychiatry. 2010;23:19–24.
   PubMed Web of Science ®Google Scholar
• Viktorin A, Lichtenstein P, Thase ME, et al. The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. Am J Psychiatry. 2014;171:1067–1073.
   PubMed Web of Science ®Google Scholar
• Gitlin MJ. Antidepressants in bipolar depression: an enduring controversy. Int J Bipolar Disord. 2018;6:25.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Keck PE, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162:1351–1360.
   PubMed Web of Science ®Google Scholar
• Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60:1079–1088.
   PubMed Web of Science ®Google Scholar
• Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171:160–168.
   PubMed Web of Science ®Google Scholar
• Durgam S, Earley W, Lipschitz A, et al. An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am J Psychiatry. 2016;173:271–281.
   PubMed Web of Science ®Google Scholar
• Cheniaux E. [The pharmacological treatment of bipolar disorder: a systematic and critical review of the methodological aspects of modern clinical trials]. Rev Bras Psiquiatr. 2011;33:72–80.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry. 1999;60:79–88.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Huffman RF, White RL, et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord. 2008;10:323–333.
   PubMed Web of Science ®Google Scholar
• Silveira LAS, Demôro Novis F, Da Silva RO, et al. Lamotrigine as an adjuvant treatment for acute bipolar depression: a Brazilian naturalistic study. Psychol Neurosci. 2013;6:109–113.
   Google Scholar
• Cheniaux E, Dias A, Lessa JLM, et al. Can lamotrigine induce switch into mania? Rev Psiquiatr Do Rio Gd Do Sul. 2005;27:206–209.
   Google Scholar
• Bloom R, Amber KT. Identifying the incidence of rash, Stevens-Johnson syndrome and toxic epidermal necrolysis in patients taking lamotrigine: a systematic review of 122 randomized controlled trials. An Bras Dermatol. 2017;92:139–141.
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20:97–170.
   PubMed Web of Science ®Google Scholar
• Souza FG, Goodwin GM. Lithium treatment and prophylaxis in unipolar depression: a meta-analysis. Br J Psychiatry. 1991;158:666–675.
   PubMed Web of Science ®Google Scholar
• Zornberg GL, Pope HG. Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol. 1993;13:397–408.
   PubMed Web of Science ®Google Scholar
• UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet. 2003;361:799–808.
   PubMed Web of Science ®Google Scholar
• Schoeyen HK, Kessler U, Andreassen OA, et al. Treatment-resistant bipolar depression: a randomized controlled trial of electroconvulsive therapy versus algorithm-based pharmacological treatment. Am J Psychiatry. 2015;172:41–51.
   PubMed Web of Science ®Google Scholar
• Cohn JB, Collins G, Ashbrook E, et al. A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol. 1989;4:313–322.
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, Shults J. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression – lack of manic induction. J Affect Disord. 2005;87:121–130.
   PubMed Web of Science ®Google Scholar
• Parker G, Tully L, Olley A, et al. SSRIs as mood stabilizers for bipolar II disorder? A proof of concept study. J Affect Disord. 2006;92:205–214.
   PubMed Web of Science ®Google Scholar
• Agosti V, Stewart JW. Efficacy and safety of antidepressant monotherapy in the treatment of bipolar-II depression. Int Clin Psychopharmacol. 2007;22:309–311.
   PubMed Web of Science ®Google Scholar
• Kane JM, Quitkin FM, Rifkin A, et al. Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison. Arch Gen Psychiatry. 1982;39:1065–1069.
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, Shults J. Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: a double-blind, placebo-substitution, continuation study. Int Clin Psychopharmacol. 2005;20:257–264.
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, Shults J. Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study. Am J Psychiatry. 2010;167:792–800.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Weisler RH, Chang W, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010;71:163–174.
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Rosenquist KJ, Ko JY, et al. Antidepressant treatment in bipolar versus unipolar depression. Am J Psychiatry. 2004;161:163–165.
   PubMed Web of Science ®Google Scholar
• Tundo A, Calabrese JR, Proietti L, et al. Short-term antidepressant treatment of bipolar depression: are ISBD recommendations useful in clinical practice? J Affect Disord. 2015;171:155–160.
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, Garcia-España F, Fawcett J, et al. Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. J Clin Psychopharmacol. 1998;18:435–440.
   PubMed Web of Science ®Google Scholar
• Amsterdam J. Efficacy and safety of venlafaxine in the treatment of bipolar II major depressive episode. J Clin Psychopharmacol. 1998;18:414–417.
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, Garcia-Espana F. Venlafaxine monotherapy in women with bipolar II and unipolar major depression. J Affect Disord. 2000;59:225–229.
   PubMed Web of Science ®Google Scholar
• Pacchiarotti I, Valentí M, Bonnin CM, et al. Factors associated with initial treatment response with antidepressants in bipolar disorder. Eur Neuropsychopharmacol. 2011;21:362–369.
   PubMed Web of Science ®Google Scholar
• Thase ME, Mallinger AG, McKnight D, et al. Treatment of imipramine-resistant recurrent depression, IV: a double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry. 1992;149:195–198.
   PubMed Web of Science ®Google Scholar
• Himmelhoch JM, Thase ME, Mallinger AG, et al. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry. 1991;148:910–916.
   PubMed Web of Science ®Google Scholar
• Silverstone T. Moclobemide vs. imipramine in bipolar depression: a multicentre double-blind clinical trial. Acta Psychiatr Scand. 2001;104:104–109.
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry. 2001;158:906–912.
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, Shults J. Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode. J Clin Psychopharmacol. 2010;30:306–311.
   PubMed Web of Science ®Google Scholar
• Simpson SG, DePaulo JR. Fluoxetine treatment of bipolar II depression. J Clin Psychopharmacol. 1991;11:52–54.
   PubMed Web of Science ®Google Scholar
• Brown EB, McElroy SL, Keck PE, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry. 2006;67:1025–1033.
   PubMed Web of Science ®Google Scholar
• Brown E, Dunner DL, McElroy SL, et al. Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression. Int J Neuropsychopharmacol. 2009;12:773–782.
   PubMed Web of Science ®Google Scholar
• Altshuler LL, Sugar CA, McElroy SL, et al. Switch rates during acute treatment for bipolar II depression with lithium, sertraline, or the two combined: a randomized double-blind comparison. Am J Psychiatry. 2017;174:266–276.
   PubMed Web of Science ®Google Scholar
• Post RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry. 2006;189:124–131.
   PubMed Web of Science ®Google Scholar
• Leverich GS, Altshuler LL, Frye MA, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry. 2006;163:232–239.
   PubMed Web of Science ®Google Scholar
• Young LT, Joffe RT, Robb JC, et al. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry. 2000;157:124–126.
   PubMed Web of Science ®Google Scholar
• Shelton RC, Stahl SM. Risperidone and paroxetine given singly and in combination for bipolar depression. J Clin Psychiatry. 2004;65:1715–1719.
   PubMed Web of Science ®Google Scholar
• Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356:1711–1722.
   PubMed Web of Science ®Google Scholar
• Vieta E, Martinez-Aran A, Goikolea JM, et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry. 2002;63:508–512.
   PubMed Web of Science ®Google Scholar
• Kupfer DJ, Chengappa KN, Gelenberg AJ, et al. Citalopram as adjunctive therapy in bipolar depression. J Clin Psychiatry. 2001;62:985–990.
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, Wang CH, Shwarz M, et al. Venlafaxine versus lithium monotherapy of rapid and non-rapid cycling patients with bipolar II major depressive episode: a randomized, parallel group, open-label trial. J Affect. 2009;112:219–230.
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, Wang G, Shults J. Venlafaxine monotherapy in bipolar type II depressed patients unresponsive to prior lithium monotherapy. Acta Psychiatr Scand. 2010;121:201–208.
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, Lorenzo-Luaces L, Soeller I, et al. Short-term venlafaxine v. lithium monotherapy for bipolar type II major depressive episodes: effectiveness and mood conversion rate. Br J Psychiatry. 2016;208:359–365.
   PubMed Web of Science ®Google Scholar
• Erfurth A, Michael N, Stadtland C, et al. Bupropion as add-on strategy in difficult-to-treat bipolar depressive patients. Neuropsychobiology. 2002;45(Suppl 1):33–36.
   PubMedGoogle Scholar
• Fogelson DL, Bystritsky A, Pasnau R. Bupropion in the treatment of bipolar disorders: the same old story? J Clin Psychiatry. 1992;53:443–446.
   PubMed Web of Science ®Google Scholar
• Sachs GS, Lafer B, Stoll AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry. 1994;55:391–393.
   PubMed Web of Science ®Google Scholar
• Grossman F, Potter WZ, Brown EA, et al. A double-blind study comparing idazoxan and bupropion in bipolar depressed patients. J Affect Disord. 1999;56:237–243.
   PubMed Web of Science ®Google Scholar
• Yatham LN, Vieta E, Goodwin GM, et al. Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: randomised double-blind placebo-controlled trial. Br J Psychiatry. 2016;208:78–86.
   PubMed Web of Science ®Google Scholar
• Amsterdam JD, Shults J. Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode. J Clin Psychopharmacol. 2008;28:171–181.
   PubMed Web of Science ®Google Scholar
• Benazzi F. Antidepressant-associated hypomania in outpatient depression: a 203-case study in private practice. J Affect Disord. 1997;46:73–77.
   PubMed Web of Science ®Google Scholar
• Altshuler LL, Suppes T, Black DO, et al. Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants. Am J Psychiatry. 2006;163:313–315.
   PubMed Web of Science ®Google Scholar
• Bottlender R, Rudolf D, Strauss A, et al. Antidepressant-associated maniform states in acute treatment of patients with bipolar-I depression. Eur Arch Psychiatry Clin Neurosci. 1998;248:296–300.
   PubMed Web of Science ®Google Scholar
• Bauer M, Rasgon N, Grof P, et al. Mood changes related to antidepressants: a longitudinal study of patients with bipolar disorder in a naturalistic setting. Psychiatry Res. 2005;133:73–80.
   PubMed Web of Science ®Google Scholar
• Lewis JL, Winokur G. The induction of mania. A natural history study with controls. Arch Gen Psychiatry. 1982;39:303–306.
   PubMed Web of Science ®Google Scholar
• Altshuler LL, Post RM, Leverich GS, et al. Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry. 1995;152:1130–1138.
   PubMed Web of Science ®Google Scholar
• Goldberg JF, Whiteside JE. The association between substance abuse and antidepressant-induced mania in bipolar disorder: a preliminary study. J Clin Psychiatry. 2002;63:791–795.
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Boiman EE, Goodwin FK. Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. J Clin Psychiatry. 2000;61:804–808.
   PubMed Web of Science ®Google Scholar
• Henry C, Sorbara F, Lacoste J, et al. Antidepressant-induced mania in bipolar patients: identification of risk factors. J Clin Psychiatry. 2001;62:249–255.
   PubMed Web of Science ®Google Scholar
• Gorwood P, Richard-Devantoy S, Sentissi O, et al. The number of past manic episodes is the best predictor of antidepressant-emergent manic switch in a cohort of bipolar depressed patients. Psychiatry Res. 2016;240:288–294.
   PubMed Web of Science ®Google Scholar
• Serretti A, Artioli P, Zanardi R, et al. Clinical features of antidepressant associated manic and hypomanic switches in bipolar disorder. Prog Neuro-Psychopharmacology Biol Psychiatry. 2003;27:751–757.
   PubMed Web of Science ®Google Scholar
• Boerlin HL, Gitlin MJ, Zoellner LA, et al. Bipolar depression and antidepressant-induced mania: a naturalistic study. J Clin Psychiatry. 1998;59:374–379.
   PubMed Web of Science ®Google Scholar
• Pacchiarotti I, Valentí M, Colom F, et al. Differential outcome of bipolar patients receiving antidepressant monotherapy versus combination with an antimanic drug. J Affect Disord. 2011;129:321–326.
   PubMed Web of Science ®Google Scholar
• Joffe RT, MacQueen GM, Marriott M, et al. Induction of mania and cycle acceleration in bipolar disorder: effect of different classes of antidepressant. Acta Psychiatr Scand. 2002;105:427–430.
   PubMed Web of Science ®Google Scholar
• Vöhringer PA, Ostacher MJ, El-Mallakh RS, et al. Antidepressants in type II versus type I bipolar depression. J Clin Psychopharmacol. 2015;35:605–608.
   PubMed Web of Science ®Google Scholar
• Coryell W, Solomon D, Turvey C, et al. The long-term course of rapid-cycling bipolar disorder. Arch Gen Psychiatry. 2003;60:914–920.
   PubMed Web of Science ®Google Scholar
• Yildiz A, Sachs GS. Do antidepressants induce rapid cycling? A gender-specific association. J Clin Psychiatry. 2003;64:814–818.
   PubMed Web of Science ®Google Scholar
• Schneck CD, Miklowitz DJ, Miyahara S, et al. The prospective course of rapid-cycling bipolar disorder: findings from the STEP-BD. Am J Psychiatry. 2008;165:370–377.
   PubMed Web of Science ®Google Scholar
• Wehr TA, Sack DA, Rosenthal NE, et al. Rapid cycling affective disorder: contributing factors and treatment responses in 51 patients. Am J Psychiatry. 1988;145:179–184.
   PubMed Web of Science ®Google Scholar
• Altshuler L, Suppes T, Black D, et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry. 2003;160:1252–1262.
   PubMed Web of Science ®Google Scholar
• Altshuler L, Kiriakos L, Calcagno J, et al. The impact of antidepressant discontinuation versus antidepressant continuation on 1-year risk for relapse of bipolar depression: a retrospective chart review. J Clin Psychiatry. 2001;62:612–616.
   PubMed Web of Science ®Google Scholar
• Joffe RT, MacQueen GM, Marriott M, et al. One-year outcome with antidepressant – treatment of bipolar depression. Acta Psychiatr Scand. 2005;112:105–109.
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Ostacher MM, El-Mallakh RS, et al. Antidepressant discontinuation in bipolar depression. J Clin Psychiatry. 2010;71:372–380.
   PubMed Web of Science ®Google Scholar
• El-Mallakh RS, Vöhringer PA, Ostacher MM, et al. Antidepressants worsen rapid-cycling course in bipolar depression: a STEP-BD randomized clinical trial. J Affect Disord. 2015;184:318–321.
   PubMed Web of Science ®Google Scholar
• Quitkin FM, Kane J, Rifkin A, et al. Prophylactic lithium carbonate with and without imipramine for bipolar 1 patients. A double-blind study. Arch Gen Psychiatry. 1981;38:902–907.
   PubMed Web of Science ®Google Scholar
• Johnstone EC, Owens DG, Lambert MT, et al. Combination tricyclic antidepressant and lithium maintenance medication in unipolar and bipolar depressed patients. J Affect Disord. 1990;20:225–233.
   PubMed Web of Science ®Google Scholar
• Wehr T, Goodwin FK. Tricyclics modulate frequency of mood cycles. Chronobiologia. 1979;6:377–385.
   PubMedGoogle Scholar
• Amsterdam JD, Lorenzo-Luaces L, Soeller I, et al. Safety and effectiveness of continuation antidepressant versus mood stabilizer monotherapy for relapse-prevention of bipolar II depression: a randomized, double-blind, parallel-group, prospective study. J Affect Disord. 2015;185:31–37.
   PubMed Web of Science ®Google Scholar
• Bauer MS, Wisniewski SR, Marangell LB, et al. Are antidepressants associated with new-onset suicidality in bipolar disorder? A prospective study of participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). J Clin Psychiatry. 2006;67:48–55.
   PubMed Web of Science ®Google Scholar
• Leon AC, Fiedorowicz JG, Solomon DA, et al. Risk of suicidal behavior with antidepressants in bipolar and unipolar disorders. J Clin Psychiatry. 2014;75:720–727.
   PubMed Web of Science ®Google Scholar
• Yerevanian BI, Koek RJ, Mintz J, et al. Bipolar pharmacotherapy and suicidal behavior. J Affect Disord. 2007;103:13–21.
   PubMed Web of Science ®Google Scholar
• Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry. 2010;11:81–109.
   PubMed Web of Science ®Google Scholar
• Fountoulakis KN, Grunze H, Vieta E, et al. The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), part 3: the clinical guidelines. Int J Neuropsychopharmacol. 2017;20:180–195.
   PubMed Web of Science ®Google Scholar
• NICE guidelines. Bipolar disorder: assessment and management [CG185]. Natl inst heal care excell. 2019.
   Google Scholar
• Goodwin G, Haddad P, Ferrier I, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016;30:495–553.
   PubMed Web of Science ®Google Scholar
• Malhi GS, Bassett D, Boyce P, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2015;49:1087–1206.
   PubMed Web of Science ®Google Scholar
• Kanba S, Kato T, Terao T, et al. Guideline for treatment of bipolar disorder by the Japanese Society of Mood Disorders, 2012. Psychiatry Clin Neurosci. 2013;67:285–300.
   PubMed Web of Science ®Google Scholar
• Bai Y-M, Chang C-J, Tsai S-Y, et al. Taiwan consensus of pharmacological treatment for bipolar disorder. J Chin Med Assoc. 2013;76:547–556.
   PubMed Web of Science ®Google Scholar
• Shah N, Grover S, Rao G. Clinical practice guidelines for management of bipolar disorder. Indian J Psychiatry. 2017;59:51.
   PubMed Web of Science ®Google Scholar
• Gijsman HJ, Geddes JR, Rendell JM, et al. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry. 2004;161:1537–1547.
   PubMed Web of Science ®Google Scholar
• Sidor MM, MacQueen GM. Antidepressants for the acute treatment of bipolar depression. J Clin Psychiatry. 2011;72:156–167.
   PubMed Web of Science ®Google Scholar
• Vázquez GH, Tondo L, Undurraga J, et al. Overview of antidepressant treatment of bipolar depression. Int J Neuropsychopharmacol. 2013;16:1673–1685.
   PubMed Web of Science ®Google Scholar
• McGirr A, Vöhringer PA, Ghaemi SN, et al. Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials. Lancet Psychiatry. 2016;3:1138–1146.
   PubMed Web of Science ®Google Scholar
• Peet M. Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants. Br J Psychiatry. 1994;164:549–550.
   PubMed Web of Science ®Google Scholar
• Fornaro M, Anastasia A, Novello S, et al. Incidence, prevalence and clinical correlates of antidepressant-emergent mania in bipolar depression: a systematic review and meta-analysis. Bipolar Disord. 2018;20:195–227.
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Wingo AP, Filkowski MA, et al. Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks. Acta Psychiatr Scand. 2008;118:347–356.
   PubMed Web of Science ®Google Scholar
• Liu B, Zhang Y, Fang H, et al. Efficacy and safety of long-term antidepressant treatment for bipolar disorders – a meta-analysis of randomized controlled trials. J Affect Disord. 2017;223:41–48.
   PubMed Web of Science ®Google Scholar
• Gitlin MJ. Antidepressants in bipolar depression: much confusion, many questions, few answers. Aust N Z J Psychiatry. 2012;46:295–297.
   PubMed Web of Science ®Google Scholar
• Ghaemi SN. Antidepressants in bipolar depression: the clinical debate. Aust N Z J Psychiatry. 2012;46:298–301.
   PubMed Web of Science ®Google Scholar
• Malhi GS. Antidepressants in bipolar depression: yes, no, maybe? Evid Based Ment Heal. 2015;18:100–102.
   PubMed Web of Science ®Google Scholar
• Azorin J-M, Kaladjian A. An update on the treatment of bipolar depression. Expert Opin Pharmacother. 2009;10:161–172.
   PubMed Web of Science ®Google Scholar
• Antosik-Wójcińska A, Stefanowski B, Święcicki Ł. Efficacy and safety of antidepressant’s use in the treatment of depressive episodes in bipolar disorder – review of research. Psychiatr Pol. 2015;49:1223–1239.
   PubMed Web of Science ®Google Scholar
• Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry. 2013;170:1249–1262.
   PubMed Web of Science ®Google Scholar
• Salvi V, Fagiolini A, Swartz HA, et al. The use of antidepressants in bipolar disorder. J Clin Psychiatry. 2008;69:1307–1318.
   PubMedGoogle Scholar
• Fornaro M, Martino M, De Pasquale C, et al. The argument of antidepressant drugs in the treatment of bipolar depression: mixed evidence or mixed states? Expert Opin Pharmacother. 2012;13:2037–2051.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Cha DS, Kim RD, et al. A review of FDA-approved treatment options in bipolar depression. CNS Spectr. 2013;18(Suppl 1):4–20.
   PubMedGoogle Scholar
• Pompili M, Verzura C, Trovini G, et al. Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders. Expert Opin Drug Saf. 2018;17:197–205.
   PubMed Web of Science ®Google Scholar
• Suttajit S, Srisurapanont M, Maneeton N, et al. Quetiapine for acute bipolar depression: a systematic review and meta-analysis. Drug Des Devel Ther. 2014;8:827.
   PubMed Web of Science ®Google Scholar
• Aoki Y, Yamaguchi S, Ando S, et al. The experience of electroconvulsive therapy and its impact on associated stigma: a meta-analysis. Int J Soc Psychiatry. 2016;62:708–718.
   PubMed Web of Science ®Google Scholar
• Wen XJ, Wang LM, Liu ZL, et al. Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder. Brazilian J Med Biol Res = Rev Bras Pesqui Medicas E Biol. 2014;47:605–616.
   PubMed Web of Science ®Google Scholar
• Tamminga CA, Kane JM. Olanzapine (Zyprexa): characteristics of a new antipsychotic. Expert Opin Investig Drugs. 1997;6:1743–1752.
   PubMedGoogle Scholar
• Altamura AC, Moro AR, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet. 1994;26:201–214.
   PubMed Web of Science ®Google Scholar
• Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry. 1999;156:702–709.
   PubMed Web of Science ®Google Scholar
• Vázquez GH, Holtzman JN, Tondo L, et al. Efficacy and tolerability of treatments for bipolar depression. J Affect Disord. 2015;183:258–262.
   PubMed Web of Science ®Google Scholar
• Taylor DM, Cornelius V, Smith L, et al. Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. Acta Psychiatr Scand. 2014;130:452–469.
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Baldwin DS, Blier P, et al. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol. 2007;22:323–329.
   PubMed Web of Science ®Google Scholar
• Angst J. The bipolar spectrum. Br J Psychiatry. 2007;190:189–191.
   PubMed Web of Science ®Google Scholar